Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes
about
Mitochondrial Quality Control and Muscle Mass MaintenanceFirst-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergeticsSerendipity and the discovery of novel compounds that restore mitochondrial plasticityDeficiency in Cardiolipin Reduces Doxorubicin-Induced Oxidative Stress and Mitochondrial Damage in Human B-LymphocytesThe normal function of the cancer kinase Mirk/dyrk1B is to reduce reactive oxygen speciesCyclophosphamide leads to persistent deficits in physical performance and in vivo mitochondria function in a mouse model of chemotherapy late effects.A splice variant of the human ion channel TRPM2 modulates neuroblastoma tumor growth through hypoxia-inducible factor (HIF)-1/2α.Anthracycline-containing chemotherapy causes long-term impairment of mitochondrial respiration and increased reactive oxygen species release in skeletal muscle.Effects of short-term endurance exercise training on acute doxorubicin-induced FoxO transcription in cardiac and skeletal muscle.Ca²⁺ entry via Trpm2 is essential for cardiac myocyte bioenergetics maintenance.Alteration of antioxidant enzymes and associated genes induced by grape seed extracts in the primary muscle cells of goats in vitro.After the chemotherapy: potential mechanisms for chemotherapy-induced delayed skeletal muscle dysfunction in survivors of acute lymphoblastic leukaemia in childhood.Acute Treatment of Resveratrol Alleviates Doxorubicin-Induced Myotoxicity in Aged Skeletal Muscle Through SIRT1-Dependent Mechanisms.Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes.The anticancer agent doxorubicin disrupts mitochondrial energy metabolism and redox balance in skeletal muscle.Oxidative stress and disuse muscle atrophy: cause or consequence?Doxorubicin inhibits muscle inflammation after eccentric exercise.BGP-15 Protects against Oxaliplatin-Induced Skeletal Myopathy and Mitochondrial Reactive Oxygen Species Production in Mice.Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin.Mitochondria: Inadvertent targets in chemotherapy-induced skeletal muscle toxicity and wasting?Targeted overexpression of mitochondrial catalase protects against cancer chemotherapy-induced skeletal muscle dysfunction.Moderate dependence of reactive oxygen species production on membrane potential in avian muscle mitochondria oxidizing glycerol 3-phosphate.Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin.Tissue retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle function.Creatine Supplementation and Doxorubicin-Induced Skeletal Muscle Dysfunction: An Ex Vivo Investigation.Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib.Physiological culture conditions alter myotube morphology and responses to atrophy treatments: implications for in vitro research on muscle wasting.
P2860
Q26770420-053455EE-B6AF-4211-82E6-5961F8671744Q28383451-44F99879-E2C8-4C0D-A5A8-DB9DE5F1EB04Q28384256-AE436A51-B194-456A-9C25-6E11C8375E38Q28552702-6686B03D-FD99-487E-8F41-C6FD0E22C0B5Q33776829-EDEF213D-BE3D-430C-A68C-EB5D5CCCFDA0Q33897890-1FBF4FBC-C59F-42AE-9371-8E6B4EC3591BQ34774611-8FA04B11-EF52-4E0C-81BC-BFA43CF5B755Q35138773-57100C22-C478-41BD-8739-2143568CCA00Q35141318-E81BF9D5-2985-4E1A-8C21-2F2D9240A314Q35178670-42BFCF47-1B6C-4178-A237-7CD1FB8F3F32Q35265075-F333870B-292D-4204-A2A0-ACA5FFF71CF2Q36778333-6BC00E06-4061-4050-BBCE-E4A54D9787FDQ36954917-6373BEB1-5E52-4E4B-A9B4-5FCE9758B1B0Q37282125-CCEA15C6-044E-4976-85B6-DB1DDCCAFC86Q37384579-01B1E279-C53C-41BF-BD05-E7ABE068A09FQ37483726-08C55C36-E066-4B0D-9BC0-0B4CA8F3389CQ37734801-B6F5314A-805C-4EC8-A44F-AAEEF574C636Q37742823-009FCA7B-84DE-4AB1-9306-08CCAB94A638Q38754829-AA8EF67B-49D9-410B-836B-FDF9CA34450DQ38831900-450EC6D7-D591-4139-89B3-BA0C4E1CF031Q40982094-01050855-D2D2-4C2A-8210-9018F00A63E0Q46675033-39EBDFDD-2677-424C-A27A-550EE39410CEQ46857381-68A50660-7CDB-4D97-BF94-277F1063B948Q47266736-0AD8D36A-32FB-4071-9168-2BBF35F39A4FQ50785546-31735814-F907-4C3C-A69F-6561B5A63D46Q55222160-3A656455-1A54-4D88-BE89-0AC68C99C57BQ55364177-79968B3B-FCC5-42BE-89DB-DFB61BE04898
P2860
Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes
@ast
Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes
@en
type
label
Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes
@ast
Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes
@en
prefLabel
Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes
@ast
Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes
@en
P2093
P2860
P1476
Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes
@en
P2093
Anne S Wilson
Elaine W Patterson
Jeffrey D Smith
Jennifer S Moylan
Laura A A Gilliam
Michael B Reid
Zaheen Rabbani
P2860
P304
P356
10.1152/AJPCELL.00217.2011
P577
2011-09-21T00:00:00Z